COVID-19 All Solid Organ Transplant Recipient Cohort Study
In a collaborative effort between NewYork-Presbyterian/Columbia and NewYork-Presbyterian/Weill Cornell Medicine, researchers share their experience across all solid organ transplants—lung, kidney, heart, and dual organ—during a 3-week period at the height of the outbreak in New York City.
- In a collaborative effort between NewYork-Presbyterian/Columbia and NewYork-Presbyterian/Weill Cornell Medicine, researchers share their experience across 90 solid organ transplant recipients—kidney (46), lung (17), liver (13), heart (9), and dual organ (5) transplants—during a 3-week period at the height of the outbreak in New York City.
- Out of the cohort, 68 were hospitalized and 23 required ICU admission (26% overall, 34% of inpatients), suggesting that transplant recipients may be at high risk of severe disease and poor outcomes.
- The authors noted that lung transplant recipients may benefit from early treatment with high-dose steroid therapy to avoid a cytokine storm, but more research is needed.
- Transplant recipients with severe disease were older, more likely to have hypertension, and had dyspnea.
- Sixteen transplant recipients died from COVID-19 complications, with a mortality rate of 24% of all inpatients and 52% of ICU patients.
Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, Arcasoy S, Aversa MM, Benvenuto LJ, Dadhania DM, Kapur S, Dove LM, Brown RS Jr, Rosenblatt RE, Samstein B, Uriel N, Farr MA, Satlin M, Small CB, Walsh TJ, Kodiyanplakkal RP, Miko BA, Aaron JG, Tsapepas DS, Emond JC, Verna EC. COVID-19 in solid organ transplant recipients: Initial report from the U.S. epicenter. American J Transplant. 2020;20(7):1800-1808.
We are committed to sharing the lessons we’ve learned from the pandemic with other centers in order to provide optimal care for patients and ensure safety for providers. In light of SARS-COV2, the Lung Transplant Program at NewYork-Presbyterian is taking special precautions. Currently, we are performing transplant procedures and providing non-emergency telemedicine visits. To refer a patient, please call (212) 305-7771.
For more information about our Transplant Program, please visit the transplant section of our website.
Advances in Transplant
Read more about our latest clinical advances.